

ORAMED PHARMACEUTICALS INC.  
Form 8-K  
February 20, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **February 14, 2018**

**ORAMED PHARMACEUTICALS INC.**  
(Exact name of registrant as specified in its charter)

|   |                          |                                      |
|---|--------------------------|--------------------------------------|
| <b>DELAWARE</b>                                   | <b>001-35813</b>         | <b>98-0376008</b>                    |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

|  |              |
|--|--------------|
| <b>Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel</b> | <b>91390</b> |
| (Address of Principal Executive Offices)                           | (Zip Code)   |

**+972-2-566-0001**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01. Entry into a Material Definitive Agreement.**

On February 14, 2018, Oramed Ltd. (the “Subsidiary”), a wholly-owned subsidiary of Oramed Pharmaceuticals Inc. (the “Company”), entered into a Clinical Research Organization Services Agreement (the “Agreement”) with Integrium, LLC (“Integrium”), effective as of November 1, 2017, to retain Integrium as a clinical research organization for the Subsidiary’s planned upcoming three-month dose-ranging clinical trial. The trial will be conducted under an Investigational New Drug application with the U.S. Food and Drug Administration, and is designed to assess the safety and evaluate the efficacy of ORMD-0801 on HbA1c on approximately 240 type 2 diabetic patients. The Agreement will terminate upon the satisfactory performance of all the services as contemplated in the Agreement.

As consideration for its services, the Subsidiary will pay Integrium a total amount of up to \$7 million that will be paid over the term of the engagement and based on the achievement of certain milestones.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ORAMED  
PHARMACEUTICALS  
INC.**

By: /s/ Nadav Kidron  
Name: Nadav Kidron  
Title: President and CEO

February 20, 2018